COMP <GO>
INNV vs USPH // RETURN ON INVESTED CAPITAL (ROIC)
InnovAge Holding Corp. (NASDAQ) VS. U.S. Physical Therapy Inc. (NYSE) • 15-METRIC TALLY: INNV 1
— USPH 10
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: USPH
LAST: $9.24 (+1.54%) • MKT CAP: $1.26B
roic
-10.20%
LAST: $86.57 (+1.47%) • MKT CAP: $1.29B
roic
11.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INNV VS. USPH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INNV | USPH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 18.00% | 19.20% | -1.20 | USPH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -10.20% | 11.50% | -21.70 | USPH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.11% | 5.81% | -3.70 | USPH | /fcf-yield <GO> |
| Operating Margin | -3.50% | 11.10% | -14.60 | USPH | /operating-margins <GO> |
| Net Profit Margin | -3.60% | 5.10% | -8.70 | USPH | /net-margins <GO> |
| Revenue Growth (YoY) | 11.80% | 16.30% | -4.50 | USPH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.12% | -2.12 | USPH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.47 | 2.94 | +1.53 | INNV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | USPH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.7 | 52.3 | -6.53 | USPH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 27.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.26B | $1.29B | -$31.0M | USPH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INNV REV | USPH REV | INNV GROSS % | USPH GROSS % | INNV FCF | USPH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $853.7M | $781.0M | 18.0% | 19.2% | $26.6M | $75.1M |
| FY 2024 | $763.9M | $671.3M | 17.3% | 18.5% | -$44.8M | $74.9M |
| FY 2023 | $688.1M | $604.8M | — | — | $20.2M | $82.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INNV // BETA —
USPH // BETA —